Avalo Therapeutics (NASDAQ:AVTX) reported quarterly losses of $(0.48) per share which beat the analyst consensus estimate of $(1.47) by 67.3 percent. This is a 127.91 percent decrease over earnings of $1.72 per share from the same period last year. The company reported $59.000 thousand in sales this quarter. This is a 69.27 percent decrease over sales of $192.000 thousand the same period last year.